8-K - OCUL - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2022

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware	001-36554	20-5560161
(State or Other Jurisdiction <br><br>of Incorporation)	(Commission<br><br>File Number)	(IRS Employer<br><br>Identification No.)

24 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code:

(781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $0.0001 par value per share	OCUL	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.

On June 16, 2022, Ocular Therapeutix, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”). At the 2022 Annual Meeting, the Company’s stockholders approved an amendment (the “2021 Stock Incentive Plan Amendment”) to the Company’s 2021 Stock Incentive Plan (the “2021 Stock Incentive Plan”). The 2021 Stock Incentive Plan Amendment, which had previously been adopted by the Company’s Board of Directors subject to stockholder approval, increased the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 3,600,000 shares.

A description of the material terms and conditions of the 2021 Stock Incentive Plan Amendment is set forth in Proposal 3 on pages 33 to 44 of the Company’s definitive proxy statement for the 2022 Annual Meeting, filed with the Securities and Exchange Commission on May 2, 2022, and is incorporated herein by reference. A complete copy of the 2021 Stock Incentive Plan, as amended, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 5.07	Submission of Matters to a Vote of Security Holders.

The following is a summary of the matters voted on at the 2022 Annual Meeting.

(1)	The Company’s stockholders elected Seung Suh Hong, Ph.D., Richard L. Lindstrom, M.D. and Leslie J. Williams as Class II directors<br>to serve until the 2025 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected<br>and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows:
Name	Votes For		Votes<br> Withheld		Broker<br> Non-Votes
---	---	---	---	---	---	---
Seung Suh Hong, Ph.D.		34,100,452		7,981,093		18,607,745
Richard L. Lindstrom, M.D.		31,374,926		10,706,619		18,607,745
Leslie J. Williams		34,258,074		7,823,471		18,607,745
(2)	The Company’s stockholders approved a non-binding, advisory proposal regarding the compensation of the Company’s named<br>executive officers. The results of the stockholders’ vote with respect to such proposal were as follows:
---	---
For		Against		Abstain		Broker Non-Votes
---	---	---	---	---	---	---	---
	31,197,580		10,723,248		160,717		18,607,745
(3)	The Company’s stockholders approved the 2021 Stock Incentive Plan Amendment to increase the number of shares of common stock<br>of the Company issuable under the 2021 Stock Incentive Plan by 3,600,000 shares. The results of the stockholders’ vote with respect<br>to such proposal were as follows:
---	---
For		Against		Abstain		Broker Non-Votes
---	---	---	---	---	---	---	---
	33,298,660		8,728,155		54,730		18,607,745
(4)	The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting<br>firm for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were<br>as follows:
---	---
For		Against		Abstain		Broker Non-Votes
---	---	---	---	---	---	---	---
	60,017,922		319,015		352,353		0
Item 9.01	Financial Statements and Exhibits.
---	---

(d) Exhibits:

99.1	Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, incorporated herein by reference to Appendix B to the Company’s<br>definitive proxy statement, filed with the Securities and Exchange Commission on May 2, 2022
104	Cover Page Interactive Data File (embedded within the Inline<br>XBRL document)
---	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.
Date: June 17, 2022	By:	/s/ Donald Notman
		Name: Donald Notman
		Title: Chief Financial Officer